GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,044 | 1,079 | 5,672 | 8,968 | 5,297 |
| Marketable Securities | 0 | 12,893 | 10,836 | 23,011 | 0 |
| TOTAL | $4,232 | $14,056 | $16,562 | $32,169 | $5,661 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 53 | 174 | 0 | 0 |
| TOTAL | $N/A | $53 | $174 | $N/A | $N/A |
| Total Assets | $4,232 | $14,109 | $16,736 | $32,169 | $5,661 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 26,303 |
| Accounts payable and accrued liabilities | 3,853 | 4,328 | 3,140 | 8,189 | 2,243 |
| Accrued Expenses | 1,797 | 1,195 | 1,669 | 1,901 | 6,134 |
| Other current liabilities | 252 | 1,052 | 19 | 138 | 383 |
| TOTAL | $5,902 | $6,633 | $4,938 | $10,259 | $35,094 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 64 | 0 | 0 |
| TOTAL | $N/A | $N/A | $64 | $N/A | $N/A |
| Total Liabilities | $5,902 | $6,633 | $5,002 | $10,259 | $35,094 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,234 | 1,381 | 1,226 | 1,070 | 946 |
| Common Shares | 2 | 1 | 33 | 1,145 | 5 |
| Retained earnings | -695,227 | -682,065 | -674,468 | -653,584 | -595,797 |
| Other shareholders' equity | 1 | 1 | 1 | 1 | 3 |
| TOTAL | $-1,670 | $7,476 | $11,734 | $21,910 | $-29,433 |
| Total Liabilities And Equity | $4,232 | $14,109 | $16,736 | $32,169 | $5,661 |